spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Allos Therapeutics 

 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2015
Cellectar Appoints Industry Veteran Jim Caruso President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Nov 2013
Novelos Therapeutics Announces a Restructuring of Its Board of Directors and Additional Changes to Its Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Feb 2013
Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2012
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Nov 2012
Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2012
Sutro Biopharma Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Apr 2012
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 20 Jan 2012
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Aug 2011
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2011
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Sep 2010
Archimedes Pharma Receives European Marketing Authorisation for PecFent(R) for the Treatment of Breakthrough Cancer Pain
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Sep 2009
Allos Therapeutics' FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jul 2009
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2008
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2007
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 20 Mar 2007
Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jan 2007
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2006
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2006
Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2006
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2006
Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Originating from Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2006
Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Patients with Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2006
FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 14 Jun 2006
Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN(TM) (efaproxiral) Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2006
Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Mar 2006
Allos Therapeutics Appoints Paul L. Berns as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2006
Allos Therapeutics Announces CEO Succession Plans
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2006
Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Originating From Breast Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 27

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 27 additional stories matching:
Allos Therapeutics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.